(NASDAQ: CRVO) Cervomed's forecast annual revenue growth rate of 134.13% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Cervomed's revenue in 2025 is $9,308,215.On average, 3 Wall Street analysts forecast CRVO's revenue for 2025 to be $44,557,921, with the lowest CRVO revenue forecast at $35,681,148, and the highest CRVO revenue forecast at $58,134,163. On average, 1 Wall Street analysts forecast CRVO's revenue for 2026 to be $41,773,051, with the lowest CRVO revenue forecast at $41,773,051, and the highest CRVO revenue forecast at $41,773,051.
In 2030, CRVO is forecast to generate $1,270,596,974 in revenue, with the lowest revenue forecast at $1,270,596,974 and the highest revenue forecast at $1,270,596,974.